Philadelphia, PA – September 6, 2018 – Liberty Property Trust has leased 4,612 square feet at 1200 Intrepid Avenue to Worldwide Express, one of the top logistics companies in North America.
In March 2017, Jefferson Health, Liberty Property Trust, and Synterra Partners announced plans for expanded services offered by Jefferson at the Navy Yard, by leasing additional space to open a 70,000-plus square-foot facility at Three Crescent Drive by early to mid-2018. Jefferson’s vision for the Navy Yard is to create a consumer-oriented healthcare destination located in a large, attractive, and highly accessible area for its patients in southeastern Pennsylvania and southern New Jersey. Read more
Jefferson Health will offer expanded services at the Navy Yard, having signed a multi-year lease agreement with Liberty Property/Synterra, a joint venture of Liberty Property Trust and Synterra Partners, for additional space to open a 70,000-plus square-foot facility at 3 Crescent Drive by early to mid-2018. Read more
Adaptimmune Therapeutics plc. (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced it will host a ribbon cutting ceremony this morning at 10:30am at the Navy Yard in Philadelphia to celebrate the opening of its newly constructed U.S. headquarters and base for clinical and manufacturing operations. Developed by Liberty Property Trust (NYSE: LPT) and Synterra Partners, and under advisement of CBRE’s Life Science Advisory and Project Management Group, Adaptimmune’s 47,400 square foot facility, located at 351 Rouse Boulevard will include a state-of-the-art cGMP manufacturing facility designed to support the Company’s clinical development objectives and the initial commercialization of novel engineered immunotherapies for cancer. Adaptimmune’s Navy Yard facility currently houses 91 employees; this number is expected to grow to 120 by the end of 2017.
Liberty Property Trust and PIDC joined WuXi AppTec, Inc., a global leader in pharmaceuticals, biopharmaceuticals, and medical devices, for a ribbon cutting ceremony to open their third facility at the Navy Yard. This new 150,000 square foot facility which, when fully operational, has the potential to accommodate an additional 200 high tech manufacturing and support jobs. Read more
Liberty Property Trust and Synterra Partners (Liberty/Synterra) and PIDC today announced that Central Green, the dynamic park located in the center of The Navy Yard, has been honored with three awards, just as Liberty/Synterra’s newest building overlooking the park, 1200 Intrepid Avenue, is scheduled to come online. Read more
Liberty Property Trust, which owns and manages more than 12 million square feet of office, flex and industrial space in the Greater Philadelphia region, today announced it has pre-leased 26,000 square feet of office space at 1200 Intrepid Avenue to Penn Capital Management Company, Inc. (PENN CAPITAL). This summer the existing Liberty tenant will relocate from Three Crescent Drive in The Navy Yard to its new, larger space, which overlooks a sustainable five-acre park, Central Green. Read more
PIDC, Philadelphia’s public-private economic development corporation, announced that The Navy Yard experienced another tremendous year of growth in 2015, adding 12 new businesses and over 500 additional employees, bringing the total counts to 152 companies and 12,000 workers. Read more
The Navy Yard is pleased to announce the addition of wifi internet in Central Green! Now while you’re running the track, reading an e-book in a hammock, having lunch on the sunlawn, or having a work meeting at the conference table, you’ll always be connected. Read more
Adaptimmune Therapeutics plc. (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced plans to locate its U.S. headquarters and clinical operations in a newly developed facility to be constructed at The Navy Yard in Philadelphia. The 47,400 square foot facility, located at 351 Rouse Boulevard in The Navy Yard’s Corporate Center, will house a state-of-the-art cGMP manufacturing facility designed to support the clinical development and initial commercialization of the Company’s novel engineered immunotherapies for cancer. Read more